3.71
Intensity Therapeutics Inc (INTS) 最新ニュース
Why Did INTS Stock Plummet 25% Today? - Stocktwits
Intensity Therapeutics (INTS) Shows Modest Decline, Holds Above Key SupportBear Flag - newsline.com
Intensity_Therapeutics - Westfair Communications
Intensity Therapeutics (INTS) Slips 5.75% as Selling Pressure Intensifies Near Key Support LevelValue Stock Ideas - newsline.com
Intensity Therapeutics Inc (INTS) Stock Price, Quote, News & History - Benzinga
INTS News | INTENSITY THERAPEUTICS INC (NASDAQ:INTS) - ChartMill
INTS Technical Analysis | Trend, Signals & Chart Patterns | INTENSITY THERAPEUTICS INC (NASDAQ:INTS) - ChartMill
Intensity Therapeutics Inc. (INTS) upgraded to buy: Here's why - MSN
INTS | Intensity Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
INTS Q1 2026 Earnings: Narrower-Than-Expected Loss as Pre-Revenue Biotech Advances Clinical PipelineEPS Surprise History - The Legal Advocate
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's Why - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Daxor (DXR) and Tonix Pharma (TNXP) - The Globe and Mail
INTS Q1 2026 Earnings: EPS Beat Despite Pre-Revenue Status; Shares Edge HigherRevenue Inflection Point - The Legal Advocate
Intensity Therapeutics Inc. (INTS) upgraded to buy: Here's what you should know - MSN
INTS Stock Price, Quote & Chart | INTENSITY THERAPEUTICS INC (NASDAQ:INTS) - ChartMill
Benchmark reiterates Intensity Therapeutics stock rating on clinical progress By Investing.com - Investing.com South Africa
Benchmark reiterates Intensity Therapeutics stock rating on clinical progress - Investing.com India
Intensity Therapeutics shares plunge 30% after $4 million discounted stock offering - MSN
Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award - ChartMill
Intensity Therapeutics Inc. (INTS) could find a support soon, here's why you should buy the stock now - MSN
How Intensity (INTS) maintains its competitive edge | Q4 2025: Earnings UnderperformMomentum Pick - Newser
Dyne Therapeutics (DYN) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
A. G. P. Maintains Intensity Therapeutics(INTS.US) With Buy Rating, Maintains Target Price $30 - Moomoo
How Intensity (INTS) talent strategy drives results | Q1 2026: Profit Exceeds ViewsAdjusted Earnings Analysis - Newser
Intensity Therapeutics (NASDAQ:INTS) Q1 2026 Results Show EPS Beat Despite No Revenue - ChartMill
8-K: Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updatemoomoo - Moomoo
Trial updates frame Intensity Therapeutics (NASDAQ: INTS) Q1 2026 loss - Stock Titan
Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Barchart.com
Intensity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
INTENSITY THERAPEUTICS ($INTS) Releases Q1 2026 Earnings - Quiver Quantitative
INTS Q1'26 Earnings: EPS estimate is (1.08) USD - TradingView
Why Intensity (INTS) ability to execute stands out (Slow Grind) 2026-05-05Top Analyst Picks - newser.com
Intensity Therapeutics (INTS) price target decreased by 12.76% to 49.98 - MSN
Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance Singapore
Intensity Therapeutics (INTS) proxy adds equity plan shares, sets 2026 virtual vote - Stock Titan
[ARS] INTENSITY THERAPEUTICS, INC. SEC Filing - Stock Titan
What Just Happened to Intra-Cellular Therapies (ITCI) Stock - Kavout
Intensity Therapeutics (INTS) price target decreased by 11.32% to 57.29 - MSN
Why Is Retail Going Gaga Over INTS Stocks Today? - MSN
Intensity Therapeutics announces pricing of $4M registered direct offering of common stock - MSN
Intensity Therapeutics (INTS) Institutional Ownership 2026 $INTS - MarketBeat
Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update - Aktiellt
大文字化:
|
ボリューム (24 時間):